Résumé
L’éjaculation prématurée est une dysfonction sexuelle très fréquente caractérisée par la perte de contrôle des éjaculations, entraînant une anxiété de performance, par conséquent une altération de la qualité de vie des patients et de leurs partenaires. La physiopathologie de ce symptôme est souvent psychogène et organique. Les causes organiques sont diverses et nécessitent une recherche systématique. Plusieurs traitements médicamenteux sont utilisés avec des taux d’efficacité variables et des effets secondaires à prendre en compte lors du choix du traitement. La prise en charge psychologique est un complément incontournable à ces traitements.
Abstract
Premature ejaculation (PE) is a frequently occurring sexual dysfunction defined by the loss of ejaculation control leading to performance anxiety and loss of self-esteem. This condition lowers the quality of life of patients and their sexual partners. The pathophysiology of PE often involves organic and psychogenic factors. Organic factors must be determined through medical examination. Several medical treatments, with varying degrees of effectiveness, are currently in use. Side effects must be taken in account when choosing treatments, and psychological care is always indicated.
This is a preview of subscription content, log in via an institution to check access.
Références
Waldinger MD, Hengevel MW, Zwinderman AH et al. (1994) Paroxetine treatment of premature ejaculation; a double blinded, randomized, placebo-controlled study. Am J Psychiatry 151: 1377–1379
Bieber I (1974) The psychoanalytic treatment of sexual disorders. J Sex Marital Ther 1: 5–15
Marson L (1994) Serotoninergic neurotoxic lesions facilitate males’ sexual reflexes. Pharmacol Biochem Behav 47: 883–888
Heaton JP (2000) Central neuropharmacological agents and mechanisms in erectile dysfunction: the role of dopamine. Neurosci Behav Rev 24: 561–569
Xin ZC (1996) Penile sensitivity in patients with primary premature ejaculation. J Urolı 56: 979–981
Waldinger MD (2002) The neurobiological approach to premature ejaculation. J Urol 168: 2359–2367
Screponi E (2001) Prevalence of chronic prostatitis in men with premature ejaculation. Urology 58: 198–202
Carani C, Isidori AM, Granata A, et al. (2005) Multi center study on the prevalence of sexual symptoms in male hypo-and hyperthyroid patients. J Clin Endocrinol Metab 90: 6472–6479
Janini E, Carosa E, Pepe M, et al. (2006) Update on pathophysiology of premature ejaculation. EAU update series 4: 141–149
Mancina R (2005) Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. Mol Hum Reprod 11: 107–115
Waldinger MD, Zwinderman AH, Schweitzer DH, et al. (2004) Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 16: 369–381
Hamilton L (1993) Determination of dapoxetine, an investigational agent with the potential for treating depression, and its mono-and di-desmethyl metabolites in human plasma using column-switching high performance liquid chromatography. J Chromatogr 612: 253–261
Hawton K (1986) Prognostic factors in sex therapy. Behav Res Ther 24: 377–385
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beley, S., Henry, N., Ciofu, C. et al. Éjaculation prématurée: définition, physiopathologie, traitements. Pelv Perineol 2, 346–349 (2007). https://doi.org/10.1007/s11608-007-0168-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11608-007-0168-3